Comparative Pharmacology
Head-to-head clinical analysis: ANKTIVA versus IMMPHENTIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANKTIVA versus IMMPHENTIV.
ANKTIVA vs IMMPHENTIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ANKTIVA is a live attenuated, nonpathogenic recombinant strain of Vibrio cholerae O1 (CVD 103-HgR) that colonizes the intestinal mucosa and elicits protective mucosal and systemic immune responses against V. cholerae, including production of vibriocidal and antitoxin antibodies.
IMMPHENTIV is an anti-PD-1 monoclonal antibody that binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1 and PD-L2 ligands, thereby restoring antitumor T-cell function.
Intravesical instillation of 300 mg (25 mL) once weekly for 6 weeks, followed by maintenance therapy of 300 mg once monthly for 6 or 12 months.
4 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; clinically, steady-state reached after 2-3 days
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~70% unchanged; fecal: ~30% as metabolites
Renal (70% as unchanged drug), biliary/fecal (30% as metabolites and unchanged drug).
Category C
Category C
Immunomodulator
Immunomodulator